An early player in the field of epigenetics and chromatin biology, EpiCypher was founded, in some measure, in response to the growing demand for high-quality reagents and tools to study chromatin regulation and enable epigenetics-focused drug development. Working in the arena of recombinant nucleosome manufacturing and development, using proprietary methods, the firm is consistently adding to the largest collection of highly pure modified recombinant designer nucleosomes (dNucs). The firm's broad dNuc diversity is providing a powerful tool to decipher the histone code and accelerate drug development. The firm leverages dNuc technology for a wide range of applications, including: SNAP-ChIP® Spike-in Controls (for antibody profiling and quantitative ChIP), EpiDyne® substrates (for characterizing chromatin remodeling enzyme complexes and inhibitors), and dCypher assays (for interrogation of epigenetic protein-histone PTM binding interactions) while also offering a suite of high-quality recombinant histone binding proteins, enzymes, peptides, antibodies, and custom assay development services to complement these platforms. Continuously pushing out the technology boundaries to deliver innovative products, solutions, and services to epigenetics and chromatin biology researchers, most recently, EpiCypher has been at the leading edge of chromatin mapping technology improvements with the recent launch of the highly sensitive epigenomic mapping CUTANA assays for ChIC, CUT&RUN, and CUT&Tag.
